Information Provided By: 
Fly News Breaks for September 22, 2017
AGN
Sep 22, 2017 | 10:32 EDT
Wells Fargo analyst David Maris says the best he can say about Allergan's data today for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis is that Cenicriviroc "seems safe and it may have a benefit in some patients." Overall, the study was not a success, but the good safety and other data support further study, Maris tells investors in a research note titled "Data Mixed, One Overhang Gone." The analyst keeps an Outperform rating on Allergan shares with a $276 price target.
News For AGN From the Last 2 Days
There are no results for your query AGN
